ETF Holdings Breakdown of NAMS

NAMS institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	27,060	USD 771,210
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	16,078	USD 458,223
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	63,866	USD 1,820,181
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	63,866	USD 1,820,181
Total =		170,870	USD 4,869,795

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with NAMS

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 9.7% on Insider Selling

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) shares were down 9.7% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $24.60 and last traded at $24.38. Approximately 255,361 shares traded hands during mid-day trading, a decline of 71% from the average daily volume […] - 2025-09-10 02:25:12

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) has been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price […] - 2025-09-02 04:26:55

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Wells Fargo & Company

Research analysts at Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $45.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 78.64% from […] - 2025-08-27 02:30:44

Zurcher Kantonalbank Zurich Cantonalbank Grows Position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) by 130.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,990 shares of the company’s stock after acquiring an additional 3,390 shares […] - 2025-08-11 04:32:58

Arizona State Retirement System Buys Shares of 10,486 NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Arizona State Retirement System purchased a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Free Report) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 10,486 shares of the company’s stock, valued at approximately $215,000. Several other large investors have also recently added to or reduced their stakes in the […] - 2025-07-23 04:54:51

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Rating of “Buy” from Analysts

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report) have been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a […] - 2025-07-14 05:38:50

NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated by Analysts at Citigroup

Stock analysts at Citigroup started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $42.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 130.77% from the stock’s current price. Other analysts […] - 2025-06-19 02:26:48

Cantor Fitzgerald Begins Coverage on NewAmsterdam Pharma (NASDAQ:NAMS)

Stock analysts at Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $42.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 115.27% from the company’s previous […] - 2025-06-06 04:30:47

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,288 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) by 6.0% during the fourth quarter, HoldingsChannel reports. The firm owned 253,571 shares of the company’s stock after buying an additional 14,288 shares during the period. UBS AM a distinct business unit of […] - 2025-06-02 05:32:58

28,517 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Bought by Lazard Asset Management LLC

Lazard Asset Management LLC acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,517 shares of the company’s stock, valued at approximately $732,000. Other institutional investors and hedge funds have […] - 2025-05-21 05:38:58

2,000 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by National Bank of Canada FI

National Bank of Canada FI purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000 shares of the company’s stock, valued at approximately $51,000. Other large investors have also recently modified […] - 2025-04-13 05:44:48

Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33

Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have been given an average rating of “Buy” by the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year […] - 2025-04-08 02:33:05

Keybank National Association OH Purchases Shares of 9,983 NewAmsterdam Pharma (NASDAQ:NAMS)

Keybank National Association OH purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,983 shares of the company’s stock, valued at approximately $257,000. Other large investors also recently bought and sold […] - 2025-03-12 05:49:05

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Brokerages

NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year […] - 2025-02-19 05:06:49

Back to Listing

Disclaimer